We are dedicated to improving the lives of those suffering from neurodegenerative diseases. We solve problems with rigorous science and innovative therapies. We have assembled a team with deep scientific, clinical, commercial, and leadership experience and expertise in medical technology and neurodegenerative diseases.
Science Officer, Co-Founder
Karl Kieburtz, MD, MPH
Renowned neurologist and former chair of the FDA peripheral and central nervous system advisory Committee and former VP of the American Neurological Association. Iinvolved with every treatment approved by FDA in the last 20 years.
Multiple neurology-related product launches (2 for PD and related movement disorders) with annual sales reaching >$350M per year. C-suite roles at Edge Therapeutics and Catalyst Pharmaceuticals. 20+ years at Eli Lilly, Lundbeck, and more.
Formerly with Medtronic, Pfizer, Siemens, Wyath, Extensive drug and device market access expertise with deep experience in Medicare, VA and private coverage, coding, and payments.
Suzanne Hendrix, PhD
Brad Wyman, PhD
VP Product Development
VP Quality & Regulatory
C. Warren Olanow, MD
Ray Chaudhuri, MD
Rajeesh Pahwa, MD
Joohi Jimenez-Shahed, MD
Dan Claassen, MD, MS
Amy Amara, MD, PhD
George Brainard, PhD
The Cycle of Innovation, Clinical Research, and Improved Lives
For decades, our founders developed innovative specialized phototherapy devices for circadian-related neuropsychiatric disorders. They validated the new devices’ safety and efficacy in human clinical trials and delivered those innovations to and improved the lives of hundreds of
They have now applied their expertise to circadian dysregulation in neurodegenerative disease. Building on this, we have created a new platform technology and developed a safe and convenient product for Parkinson’s patients. PhotoPharmics is now validating this product in robust clinical research. After demonstrating safety and efficacy, these products will become widely available for people with Parkinson’s.
In addition to improving the lives of Parkinson’s patients, recent science and clinical evidence leads us to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s to other age-related neurodegenerative diseases. We will validate those products in clinical research, and if successful, deliver the solutions to individuals who suffer from these diseases.